Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with PertuzumabOtto Metzger, Ian E. Krop, Giuseppe Viale et al.|Cancer Discovery|2021Cited by 241
HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial.Otto Metzger, Ian E. Krop, Giuseppe Viale et al.|Journal of Clinical Oncology|2019Cited by 82
Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factorsAdrienne G. Waks, Lindsey R. Baden, Sara M. Tolaney et al.|Breast Cancer Research and Treatment|2015Cited by 43
HER2 heterogeneity and treatment response–associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trialZheqi Li, Kornélia Polyák, Otto Metzger et al.|Journal of Clinical Investigation|2024Cited by 29
Sequential combination of sacituzumab govitecan and talazoparib in metastatic triple negative breast cancer (mTNBC): Results from a phase II study.Rachel O. Abelman, Aditya Bardia, Dejan Juric et al.|Journal of Clinical Oncology|2024Cited by 6